<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nichols, Emma Hitt</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Birnie, David</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Continued Warfarin Better than Heparin Bridging during Device Implantation</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-06-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">10-10</style></pages><abstract><style  face="normal" font="default" size="100%">Importantly, up to 35% of patients that undergo arrhythmic device implantation also require chronic anticoagulant treatment. Current clinical practice guidelines recommend discontinuing warfarin treatment prior to surgery and treating patients with low-molecular-weight heparin [Douketis JD et al. Chest 2012]. This article presents data from the Bridge or Continue Coumadin for Device Surgery Randomized Controlled Trial [BRUISE CONTROL; Birnie D et al. N Engl J Med 2013], which tested the hypothesis that continued treatment with warfarin would reduce the number of device-pocket hematomas without increasing the risk of major perioperative bleeding events.</style></abstract><number><style face="normal" font="default" size="100%">3</style></number><volume><style face="normal" font="default" size="100%">13</style></volume></record></records></xml>